Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT, Chemotherapy, and Cadonilimab Neoadjuvant Therapy for TNBC
NCT06401005Phase 2Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in triple-negative breast cancer (TNBC), sponsored by Hubei Cancer Hospital. Primary endpoint: Complete pathologic remission rate at 30 weeks. Started Nov 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06401005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401005.